Objective: The aim of this study was to investigate the association of blood urine nitrogen (BUN) levels with all-cause mortality in ST-segment elevation myocardial infarction (STEMI).
INTRODUCTION
Risk stratification of patients with acute coronary syndrome (ACS), which is the leading cause of death worldwide 1 , is so important in order to initiate appropriate medical treatment. There are several parameters used for prediction of mortality in ACS [2] [3] [4] [5] [6] [7] . An increase in serum creatinine (sCr) levels has been found as a predictor of adverse events and mortality in ACS [7] [8] [9] [10] [11] . Despite the fact that blood urea nitrogen (BUN) is another commonly used parameter to evaluate kidney function in routine clinical practice, the impact of increased BUN levels on mortality in ACS has not been well established yet. The aim of this study was to investigate the association of BUN levels with all-cause mortality and major cardiac events (MACE) in ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (pPCI).
MATERIAL AND METHODS

Study participants
This retrospective study included 3844 consecutive patients with STEMI undergoing pPCI from January 2008 to December 2011 at the tertiary research hospital of a high volume center (1194 pPCI and 2032 elective PCI were performed by 25 interventional cardiologists in 2010). The only exclusion criterion was current renal replacement therapy. A total of 26 patients were excluded because of having at least one of the exclusion criteria. An additional 12 patients were excluded from the study due to the fact that BUN measurements were not performed at admission. An additional 28 patients were excluded from the study due to loss to follow-up. All follow-up data were obtained from hospital medical records or by interviewing (directly or by telephone) patients, their families, or their personal physicians. The study was terminated after a follow-up period of 36 months. The study was approved by the Institutional Ethics Committee.
Analysis of patient data
A clinical history of risk factors, such as age, gender, hypertension, diabetes mellitus, hyperlipidemia, renal insufficiency was determined from the hospital's medical database. Echocardiographic and coronary angiographic findings were also obtained from the same database. An echocardiogram was performed in 93 % patients at first 48 hours in the coronary care unit and left ventricular ejection fraction (LVEF) was calculated by using Simpson method 12 . Nonionic low osmolality contrast media was used in all patients (616 mosmol/kg). The occurrences of in-hospital and long-term events were evaluated by a trained study coordinator. Following coronary angiography or pPCI, the patients were admitted to coronary care unit for follow-up monitorization. The estimated glomerular filtration rate (eGFR) was calculated by using Cockcroft-Gault equation 13 . The drugs were administered during and after the hospitalization according to the European Society of Cardiology Guidelines 14 . Acute kidney injury is defined as an increase in serum creatinine level of ≥0.5 mg/dL or a relative 25 % increase from baseline creatinine value, assessed at 48 hours after the angiography 15 . Blood values obtained from venous blood samples at hospital admission were recorded from the medical reports. White blood cell, hemoglobin level, and platelet counts were measured as a part of the automated complete blood count using a Coulter LH 780 Hematology Analyzer (Beckman Coulter Ireland, Inc, Galway, Ireland). Biochemical measurements were performed using Siemens Healthcare Diagnostic Products kits and calibrators (Marburg, Germany). Creatine kinase isoenzyme-MB (CK-MB) levels were measured using an immune-inhibition method (Architect C 8000; Abbott Inc).
Angiographic analysis
All patients underwent pPCI within 60 minutes of admission. All pPCI procedures were performed using the standard femoral approach with a 6-Fr guiding catheter. Medication before the pPCI included 600 mg of clopidogrel and 300 mg of chewable aspirin. Direct stenting was performed whenever possible; in the remaining cases, balloon predilatation was performed. The drugeluting stent was used whenever possible. To achieve maximal dilation, an intracoronary injection of nitroglycerin (100 µg) was administered in each coronary angiogram. All patients were treated with maintenance doses of clopidogrel (75 mg once daily for 12 months) and aspirin (100 mg indefinitely).
Endpoints
The primary endpoints were the incidence of inhospital and long-term all-cause mortality. The secondary endpoint was MACE, which includes all-cause death, non-fatal acute coronary syndrome (ACS), and target lesion revascularization (TLR). Evaluation of MACE was obtained from hospital's medical database or by follow-up interviews (directly or by telephone).
Definition of short-term and long-term events
TLR was defined as vascularization of the stented segment or within 5-mm margins proximal or distal to the stent by either repeat PCI or coronary artery bypass grafting. Non-fatal ACS was described as a 2-fold increase in serum CK-MB enzyme levels and/or ST segment re-elevations. Stent thrombosis and in-hospital ventricular arrhythmias were also analyzed. Stent thrombosis was defined as an abrupt onset of cardiac symptoms along with an elevation in levels of biomarkers or electrocardiographic evidence of myocardial injury after stent deployment in the first 24 h. This was accompanied by angiographic evidence of a flow-limiting thrombus near a previously placed coronary stent.
Statistical analysis
In a first step, an admission BUN of 17.5 mg/dL was identified through a ROC analysis as an optimal cutoff value to predict the in-hospital mortality. Two groups were formed accordingly: one with 2328 patients (BUN < 17.5) and the other with 1450 patients (BUN ≥ 17.5). In a second step, baseline characteristics were compared between two groups. Kolmogorov-Smirnov test was used for testing of normality. All continuous variables showed skewed distributions and expressed as median and, 25th and 75th percentiles; and compared using the Kruskal-Wallis test. Categorical variables were expressed as number and percentages, and Pearson's chi-square or Fisher's exact tests were used to evaluate the differences. In a third step, to analyze the prediction for in-hospital mortality, data from the admission parameters were employed as independent variables. The univariate relationship between baseline characteristics and in-hospital mortality were assessed by univariate hierarchical logistic regression analysis. Multivariate analysis by stepwise logistic regression models (backward elimination) tested variables that were significant at p<0.1 in the univariate analysis. In a fourth step, after a mean follow-up period of 33±0.14 months, the median survival times (MST) of two groups were compared using the Kaplan-Meier survival method. Overall survival was calculated from the day of diagnosis to the day of death or last follow-up. Differences between the groups were analyzed by the log-rank test. A forward Cox proportional regression model was used for multivariable analysis. The univariate relationship between baseline characteristics and long-term mortality were assessed by univariate Cox regression analysis. Multivariate analysis by stepwise Cox regression models (backward elimination) tested variables that were significant at p<0.1 in the univariate analysis. A two-tailed pvalue of <0.05 was considered as statistically significant, and 95% CIs were presented for all odds ratios and hazard ratios. Analyses were performed using Statistical Package for Social Sciences software, version 16.0 (SPSS; IBM, Armonk, New York, USA).
RESULTS
A total of 3778 patients (mean age 58.3± 11.8 years; men 81%) with STEMI were included. The patients' baseline characteristics, categorized by admission BUN, are listed in Table 1 . There was a significant difference in terms of age (p<0.001) and gender (p<0.001) among the subgroups of BUN. The history of patients was similar in terms of hyperlipidemia (p=0.632), current smoking status (p=0.280) and previous PCI (p=0.375). Whereas, the history of patients was significantly different in terms of hypertension (p<0.001), diabetes mellitus (p<0.001), previous MI (p=0.009), previous CABG (p=0.003), and chronic kidney disease (p<0.001). At admission, the groups were similar in terms of systolic blood pressure (p=0.069), diastolic blood pressure (p=0.921), heart rate (p=0.254), Killip class (p=0.243), LVEF (p=0.076), and anterior myocardial infarction incidence (p=0.161). Patients' chest-pain-period and door-to-balloon-time were similar (p=0.383 and p=0.103 respectively).
The patients' laboratory parameters are summarized in Table 1 . In laboratory parameters, the patients showed significant differences by the respect of admission creatinine (p<0.001) and eGFR (p<0.001). Whereas; the groups were similar with respect to CK-MB (p=0.060), peak CK-MB (p=0.083), white blood cell count (p=0.214), hematocrit (p=0.159) and platelet count (p=0.195). The patients' coronary angiographic parameters are summarized in Table  1 . The patients with higher BUN levels had significantly higher 3-vessels disease (p<0.001). The type of PCI and stent were similar between the groups. Generally, TIMI flow grades between the groups were similar before the intervention. However, patients with higher BUN levels had significantly lower TIMI III flow grade ratios after intervention compared to patients with lower BUN levels. Table 2 presents the in-hospital and long-term clinical outcomes of the study population. During hospitalization, patients with higher BUN levels showed significantly higher cardiogenic shock, acute respiratory failure, ventricular arrhythmia, MACE, and mortality rate compared to patients with lower BUN levels. An admission BUN of 17.5 mg/dL was identified through a ROC analysis as an optimal cutoff value to predict the inhospital mortality with 68% sensitivity and 66% specificity (AUC: 0.75; 95% CI:0.72-0.88; p < 0.001) (Figure 1 ). The patients were followed up for a mean period of 33 ± 0.1 months. At the out-hospital course, patients with higher BUN levels showed significantly higher MACE and all-cause mortality rate compared to patients with lower BUN levels. The 3-year Kaplan-Meier curve for overall survival in patients with lower and higher BUN levels were 96.3% and 81.5%, respectively ( Figure 1 ). 
DISCUSSION
The mechanisms of acute kidney injury in the setting of cardiac systolic and/or diastolic dysfunction have not been well established due to the lack of studies. The reduction of cardiac output is not the only reason to explain the reduction in GFR. Ljungman et al. 16 found that GFR was not reduced until the cardiac index dropped to <1.6 L/min. There are several studies suggesting that fluid overload which results in renal venous congestion may be the main mechanism of renal dysfunction in cardiac dysfunction. Nohria et al. 17 , which was supported by another study 18 , demonstrated that only the higher CVP correlated with the lower GFR among all hemodynamic parameters.
In prerenal azotemia, urea increases disproportionately to sCr on account of enhanced proximal tubular reabsorption that follows the enhanced transport of water and sodium 19 . In distal nephron, urea reabsorption depends on antidiuretic hormone 20 , which is potentiated by angiotensin II 21 . Hence, in addition to reflecting kidney function, BUN levels can reflect a state of hypoperfusion. We hypothesized that BUN might be a good indicator for renal hypoperfusion as a result of cardiac systolic and/or diastolic dysfunction in the setting of coronary ischemia. Despite the fact that multiple etiologies other than renal hypoperfusion, such as gastrointestinal (GI) bleeding, may explain BUN elevations at baseline; GI bleeding was rare in our study population (n=8). Hence, hemodynamic factors were most likely to contribute to elevated BUN levels in our study population. Another reason for choosing BUN instead of sCr was that it remains constant throughout the aging process. Elderly patients may tend to have sCr levels within normal range despite the fact that their renal function is severely compromised; due to decreased muscle mass 22, 23 . In our study, the ROC analysis established that the area under the curve for BUN (AUC: 0.75; 95% CI 0.72 to 0.88; p<0.001) was higher than that of creatinine (AUC: 0.69; 95% CI 0.65 to 0.74; p<0.001).
The impact of elevated BUN on mortality in the setting of acute decompensated heart failure (ADHF) has been shown in some large-scale studies. Aronson et al. 24 studied 541 patients with a previous diagnosis of heart failure admitted for clinical decompensation. They found that elevated BUN level was a predictor of mortality in patients admitted for ADHF. In a large-scale study also showed that high admission level of BUN was the best single predictor of mortality in patients with ADHF 25 . Thus, the association of BUN levels with mortality in ADHF has been established in a large-scale study.
Some studies have already shown an association between BUN levels and mortality in patients with ACS. Kirtane et al. 26 studied 9420 patients with ACS, and they found a correlation between increased BUN level and mortality. Their study population consisted of both STEMI (30%) and non-STEMI (70%) patients. Another prospective study included both STEMI and non-STEMI patients showed that increased BUN level was associated with in-hospital mortality 27 . However, our study population consisted of only patients with STEMI treated with pPCI. This difference limits the direct comparison of two studies. Aronson et al. 28 studied 1507 patients with STEMI treated with thrombolytic therapy or pPCI, and they showed the relationship between elevated BUN levels and long-term mortality. In spite of the fact that the study population was not homogeneous in terms of treatment, they included only STEMI patients and our study supports their findings indicating that elevated BUN level predicts long-term of mortality. Our study showed that an increase in BUN levels was independently associated with a high risk of in-hospital and longterm all-cause mortality, and MACE (Table 3) . Patients with higher BUN levels on admission had 5.3-times higher in-hospital and 5-times higher long-term mortality rates, which had higher sensitivity and specificity over sCr levels. 
Limitations
There are some limitations of our study. A total of 66 patients were excluded from the study due to inaccurate recording of the laboratory results and historical data. Thus, neither in-hospital nor longterm mortality was assessed for those patients. Our population was limited to patients with STEMI undergoing pPCI. Hence our results should not be generalized to all patients with ACS. There were significant differences in terms of gender and age between two groups. It might affect the findings of the study. The study was carried out in a single tertiary referral heart center. On account of the fact that high-risk patients are referred for pPCI to our heart center, it may have affected our results. So, there was a possibility of selection bias although great attention was paid to include all consecutive STEMI patients managed with pPCI to avoid selection bias. Another limitation of the study originates from the nature of retrospective design. We were not able to reach all baseline characteristics and follow-up parameters, which can affect the eGFR of the patients such as body mass index, medications, and the daily urine output. 
CONCLUSION
